It is all about % not the actual amount. Buying 1000 shares at $1.65 puts $1,650 at risk and a 3.6% increase in one day yields $59.40
Purchasing 1000 shares of Apple at $94.00 per share puts $94,000 at risk and a 3.6% increase in one day yields $3,384.
Probably, but the plan then was most likely based on the idea that the revenue stream from Belviq would be larger. It's also very difficult for R&D scientists to make decisions to lay off fellow scientists and research types. Munshi was able to come in and look at financials and do what had to be done in order to survive.
Munshi didn't join Arena and take a 3.8 million share option package at $1.55 a share which vests over the next few years and plan to fail. Cutting R&D staff and focusing on the multiple compounds already in trials was the right call.
I would disagree. For a small cap pharma, there are plenty of compounds already being evaluated and in agreements with JV pharmas. It's time to reduce spending on more research & patent filing and move forward with compounds already in clinical trials, etc.
Focus on finances & moving compounds already in clinical trials along. Probably don't need to have staff continue to do R&D lab work & file patents. Old management were Phds who could only focus on science R&D and not finances. There is an old saying in the world of R&D; Sometimes scientists & engineers need adult supervision"
Since this board has nothing to do with thought out views, I thought I'd post something just as silly. :-)
$10 in 2017 is likely though.
Sentiment: Strong Buy